Effects of Lapatinib on HER2-Positive and HER2-Negative Canine Mammary Carcinoma Cells Cultured In Vitro
Open Access
- 17 June 2021
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 13 (6) , 897
Abstract
HER2 is a prognostic and predictive marker widely used in breast cancer. Lapatinib is a tyrosine kinase inhibitor that works by blocking the phosphorylation of the receptor HER2. Its use is related to relatively good results in the treatment of women with HER2+ breast cancer. Thus, this study aimed to verify the effects of lapatinib on four canine primary mammary gland carcinoma cell cultures and two paired metastatic cell cultures. Cultures were treated with lapatinib at concentrations of 100, 500, 1000 and 3000 nM for 24 h and the 50% inhibitory concentration (IC50) for each cell culture was determined. In addition, a transwell assay was performed to assess the ability of lapatinib to inhibit cell migration. Furthermore, we verified HER2 expression by RT-qPCR analysis of cell cultures and formalin-fixed paraffin-embedded tissues from samples corresponding to those used in cell culture. Lapatinib was able to inhibit cell proliferation in all cell cultures, but it was not able to inhibit migration in all cell cultures. The higher the expression of HER2 in a culture, the more sensitive the culture was to treatment. This relationship may be an indication that the expression of HER2 may be a predictive factor and opens a new perspective for the treatment of primary and metastatic mammary gland cancer.Keywords
Funding Information
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (001)
- Fundação de Amparo à Pesquisa do Estado de São Paulo (2018/14041-4)
This publication has 54 references indexed in Scilit:
- Her2 activation mechanism reflects evolutionary preservation of asymmetric ectodomain dimers in the human EGFR familyeLife, 2013
- Prognostic Value of Histological Grading in Noninflammatory Canine Mammary Carcinomas in a Prospective Study With Two-Year Follow-UpVeterinary Pathology, 2012
- Lapatinib for Advanced or Metastatic Breast CancerThe Oncologist, 2012
- Comparative oncology: ErbB-1 and ErbB-2 homologues in canine cancer are susceptible to cetuximab and trastuzumab targetingMolecular Immunology, 2012
- Tyrosine kinase inhibitors: Multi-targeted or single-targeted?World Journal of Clinical Oncology, 2011
- In vitro anti‐myeloma activity of the Aurora kinase inhibitor VE‐465British Journal of Haematology, 2009
- The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-2 Therapy and Personalized MedicineThe Oncologist, 2009
- The ErbB receptors and their role in cancer progressionExperimental Cell Research, 2003
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences, 2001